ALLMedicine™ Cavernous Sinus Thrombosis Center

Jun 28th, 2022 - A heavy burden of cranio-maxillofacial complications may be encountered in corona virus disease-2019 patients due to the associated coagulopathy and inflammatory consequences of the disease. This study aims to describe clinical and radiographic fe...

Apr 23rd, 2022 - Septic cavernous sinus thrombosis (SCST) is a rare but life-threatening condition that commonly arises from infections, including paranasal sinusitis, otitis media, and skin infection. Meanwhile, head trauma as a predisposing factor of SCST has be...

Apr 7th, 2022 - Diagnostic Considerations Failure to recognize necrotizing (ie, malignant) otitis externa (OE) is a significant pitfall. A patient who is diabetic or immunocompromised with severe pain in the ear should have necrotizing OE excluded by an otolaryng...

Mar 21st, 2022 - Pediatric cavernous sinus thrombosis (CST) is a rare condition with limited data regarding its clinical characteristics and long-term outcomes. The objective of this study was to describe the clinical and radiologic features, diagnostic evaluation...

Mar 8th, 2022 - Cavernous sinus thrombosis is a rare and often fatal condition, usually associated with infections in the head and neck region. Clinical presentation includes fever, headache, and periorbital swelling. Mortality can be high; however, prompt treatm...

Sep 9th, 2019 - Infection with Candida auris likely led to panophthalmitis and vision loss in an immune compromised patient, according to a case report published online today in the Annals of Internal Medicine. Vinayak Shenoy, DO, and colleagues at Lenox Hill Hos...

Jul 10th, 2017 - Once-weekly prophylactic therapy with emicizumab (ACE910) was associated an 87% lower rate of treated bleeding than no prophylaxis among patients with hemophilia A with inhibitors in the open-label, phase III HAVEN 1 trial. After a median 24 weeks.

Jul 10th, 2017 - Once-weekly prophylactic therapy with emicizumab (ACE910) was associated an 87% lower rate of treated bleeding than no prophylaxis among patients with hemophilia A with inhibitors in the open-label, phase III HAVEN 1 trial. After a median 24 weeks.

Feb 2nd, 2016 - This patient had a severe case of periorbital cellulitis. The ENT doctor ordered a computed tomography scan of the sinuses, which showed ethmoid and maxillary sinusitis on the right side with some proptosis.